On May 31, Kentucky’s Opioid Abatement Advisory Commission announced that it will be allocating approximately $42 million from the state’s Opioid Settlement Fund to research the psychedelic drug, ibogaine.
This decision — framed as a way to combat opioid dependence in the future — is misguided, and funds could be used in a number of ways that would be more immediately beneficial to drug users and those struggling with addiction.
Read the full opinion piece published at the Courier-Journal.